350 related articles for article (PubMed ID: 28471660)
1. Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier.
Monaco I; Camorani S; Colecchia D; Locatelli E; Calandro P; Oudin A; Niclou S; Arra C; Chiariello M; Cerchia L; Comes Franchini M
J Med Chem; 2017 May; 60(10):4510-4516. PubMed ID: 28471660
[TBL] [Abstract][Full Text] [Related]
2. Targeted and effective glioblastoma therapy via aptamer-modified tetrahedral framework nucleic acid-paclitaxel nanoconjugates that can pass the blood brain barrier.
Shi S; Fu W; Lin S; Tian T; Li S; Shao X; Zhang Y; Zhang T; Tang Z; Zhou Y; Lin Y; Cai X
Nanomedicine; 2019 Oct; 21():102061. PubMed ID: 31344499
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
Salphati L; Heffron TP; Alicke B; Nishimura M; Barck K; Carano RA; Cheong J; Edgar KA; Greve J; Kharbanda S; Koeppen H; Lau S; Lee LB; Pang J; Plise EG; Pokorny JL; Reslan HB; Sarkaria JN; Wallin JJ; Zhang X; Gould SE; Olivero AG; Phillips HS
Clin Cancer Res; 2012 Nov; 18(22):6239-48. PubMed ID: 22992516
[TBL] [Abstract][Full Text] [Related]
4. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
5. Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
Salphati L; Alicke B; Heffron TP; Shahidi-Latham S; Nishimura M; Cao T; Carano RA; Cheong J; Greve J; Koeppen H; Lau S; Lee LB; Nannini-Pepe M; Pang J; Plise EG; Quiason C; Rangell L; Zhang X; Gould SE; Phillips HS; Olivero AG
Drug Metab Dispos; 2016 Dec; 44(12):1881-1889. PubMed ID: 27638506
[TBL] [Abstract][Full Text] [Related]
6. Aptamer-Based In Vivo Therapeutic Targeting of Glioblastoma.
Cesarini V; Scopa C; Silvestris DA; Scafidi A; Petrera V; Del Baldo G; Gallo A
Molecules; 2020 Sep; 25(18):. PubMed ID: 32957732
[TBL] [Abstract][Full Text] [Related]
7. Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice.
Qin H; Jiang Y; Zhang J; Deng C; Zhong Z
Mol Pharm; 2019 Aug; 16(8):3711-3719. PubMed ID: 31299161
[TBL] [Abstract][Full Text] [Related]
8. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
[TBL] [Abstract][Full Text] [Related]
9. Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.
Becker CM; Oberoi RK; McFarren SJ; Muldoon DM; Pafundi DH; Pokorny JL; Brinkmann DH; Ohlfest JR; Sarkaria JN; Largaespada DA; Elmquist WF
Neuro Oncol; 2015 Sep; 17(9):1210-9. PubMed ID: 25972455
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive nanoparticle strategies for brain tumor targeting.
Sun C; Ding Y; Zhou L; Shi D; Sun L; Webster TJ; Shen Y
Nanomedicine; 2017 Nov; 13(8):2605-2621. PubMed ID: 28756093
[TBL] [Abstract][Full Text] [Related]
11. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
[TBL] [Abstract][Full Text] [Related]
12. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
[TBL] [Abstract][Full Text] [Related]
13. Dual functional nanoparticles efficiently across the blood-brain barrier to combat glioblastoma
Jin Z; Piao L; Sun G; Lv C; Jing Y; Jin R
J Drug Target; 2021 Mar; 29(3):323-335. PubMed ID: 33108906
[TBL] [Abstract][Full Text] [Related]
14. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics.
Tang W; Fan W; Lau J; Deng L; Shen Z; Chen X
Chem Soc Rev; 2019 Jun; 48(11):2967-3014. PubMed ID: 31089607
[TBL] [Abstract][Full Text] [Related]
15. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.
Choudhury H; Pandey M; Chin PX; Phang YL; Cheah JY; Ooi SC; Mak KK; Pichika MR; Kesharwani P; Hussain Z; Gorain B
Drug Deliv Transl Res; 2018 Oct; 8(5):1545-1563. PubMed ID: 29916012
[TBL] [Abstract][Full Text] [Related]
16. Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme.
Saxena V; Hussain MD
Colloids Surf B Biointerfaces; 2013 Dec; 112():350-5. PubMed ID: 24012704
[TBL] [Abstract][Full Text] [Related]
17. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
18. New strategies for cancer management: how can temozolomide carrier modifications improve its delivery?
Sharma S; Italiya K; Mittal A; Chitkara D
Ther Deliv; 2017 Jul; 8(7):475-477. PubMed ID: 28633588
[No Abstract] [Full Text] [Related]
19. Nanoparticles: Novel vehicles in treatment of Glioblastoma.
Pourgholi F; Hajivalili M; Farhad JN; Kafil HS; Yousefi M
Biomed Pharmacother; 2016 Feb; 77():98-107. PubMed ID: 26796272
[TBL] [Abstract][Full Text] [Related]
20. Use of nanoparticles for glioblastoma treatment: a new approach.
Játiva P; Ceña V
Nanomedicine (Lond); 2017 Oct; 12(20):2533-2554. PubMed ID: 28952878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
